LBPH News and Press, Longboard Pharmaceuticals Inc. From 11/03/22

LP352 Phase 1b/2a PACIFIC Study in participants with a range of developmental and epileptic encephalopathies (DEEs) ages 12-65 on track for topline data in second half 2023 Phase 1 open-label study to assess central nervous system (CNS) pharmacokinetics (PK) and pharmacodyna...

SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Kevin Lind, Longboard’s President & C...

Gainers: Axsome Therapeutics AXSM +31% . Summit Therapeutics SMMT +25% . Assure Holdings ( IONM ) +13% . Longboard Pharmaceuticals ( LBPH ) +10% . TransCode Therapeutics ( RNAZ ) +8% . Losers: Accelerate Diagnostics AXDX -27...

Longboard Pharmaceuticals press release ( NASDAQ: LBPH ): Q2 GAAP EPS of -$0.67 misses by $0.13 . Cash, cash equivalents and short-term investments were approximately $87.4 million. Cash position is expected to support operations into 2024 based on our current business...

LP352 Phase 1b/2a PACIFIC Study remains on track for completion in the second half of 2023; recently expanded the participant age range to 12-65 years old and added open-label extension study Initiated a Phase 1 open-label study to assess central nervous system (CNS) pharmacok...

SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Brandi Roberts, Longboard’s Chief Financia...

SAN DIEGO, June 07, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Kevin Lind, Longboard’s President & CE...

SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its leadership team will participate i...

SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior leadership team will partici...

Longboard Pharmaceuticals press release (NASDAQ:LBPH): Q1 GAAP EPS of -$0.56. At March 31, 2022, Longboard’s cash, cash equivalents and short-term investments were approximately $96.1 million. Our cash position is expected to support operations into 2024 based on our current business p...